Corient Private Wealth LLC Sells 1,615 Shares of Waters Co. (NYSE:WAT)

Corient Private Wealth LLC lessened its stake in Waters Co. (NYSE:WAT) by 22.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,564 shares of the medical instruments supplier’s stock after selling 1,615 shares during the quarter. Corient Private Wealth LLC’s holdings in Waters were worth $2,064,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Bank of Jackson Hole Trust bought a new stake in shares of Waters in the fourth quarter valued at $34,000. Fortitude Family Office LLC increased its holdings in Waters by 235.7% in the 4th quarter. Fortitude Family Office LLC now owns 94 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 66 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in Waters by 129.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 94 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 53 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Waters by 54.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 125 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 44 shares during the last quarter. Finally, R Squared Ltd bought a new position in Waters during the fourth quarter worth about $63,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on WAT shares. Scotiabank upgraded shares of Waters from a “sector perform” rating to a “sector outperform” rating and upped their price target for the company from $430.00 to $450.00 in a research note on Thursday, February 13th. UBS Group raised their price target on Waters from $405.00 to $410.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th. Barclays upgraded Waters from an “underweight” rating to an “equal weight” rating and lifted their price target for the company from $360.00 to $415.00 in a research report on Monday, February 10th. Wells Fargo & Company increased their price objective on Waters from $415.00 to $420.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Finally, Bank of America reduced their target price on Waters from $430.00 to $410.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Eleven analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Waters currently has a consensus rating of “Hold” and a consensus price target of $391.07.

Waters Stock Performance

NYSE WAT opened at $373.07 on Tuesday. Waters Co. has a 52-week low of $279.24 and a 52-week high of $423.56. The company has a fifty day moving average of $390.29 and a 200-day moving average of $371.85. The company has a market capitalization of $22.16 billion, a P/E ratio of 34.83, a P/E/G ratio of 3.79 and a beta of 1.00. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.65 and a current ratio of 0.94.

Waters (NYSE:WAT) last posted its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.02 by $0.08. Waters had a return on equity of 46.31% and a net margin of 21.56%. As a group, equities research analysts predict that Waters Co. will post 12.86 EPS for the current fiscal year.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.